English
Surgical excision is first line treatment of all types of basal cell carcinoma r9
Local low-risk basal cell carcinoma r1
Local high-risk basal cell carcinoma r1
Nodal or distant metastatic disease r1
Medication | Common regimens | Life-threatening or dose-limiting adverse reactions | Notable or nonemergent adverse reactions | Special considerations |
---|---|---|---|---|
Antimetabolite - nucleoside metabolic inhibitor | ||||
Fluorouracil (topical) | • Fluorouracil (topical) monotherapy | • Photosensitivity | • Allergic contact dermatitis • Skin burning • Crusting • Leukocytosis • Pruritus • Rash • Scarring • Soreness • Ulceration | • Increased risk of serious or fatal adverse reactions in patients with low or absent dihydropyrimidine dehydrogenase activity |
Epidermal growth factor receptor (EGFR) antagonist | ||||
Cetuximab | • Cetuximab monotherapy | • Cardiopulmonary arrest • Dermatologic toxicity • Infusion-related reactions • Interstitial lung disease (ILD) • Radiation recall | • Diarrhea • Electrolyte abnormalities • Headache • Infection | • Effective contraception required during and after therapy for 2 months for females of reproductive potential |
Hedgehog pathway inhibitor | ||||
Sonidegib | • Sonidegib monotherapy | • Increased creatine phosphokinase (CPK) • Muscle cramps • Musculoskeletal pain • Premature epiphyseal fusion • Myalgia | • Abdominal pain • Alopecia • Anorexia • Diarrhea • Dysgeusia • Fatigue • Headache • Nausea/vomiting • Pain • Pruritus • Weight loss | • Advise patients not to donate blood or blood products during treatment and for at least 20 months after the last dose • Advise males not to donate semen during and after therapy for at least 8 months after the last dose • Effective contraception required during and after therapy for at least 20 months for females of reproductive potential and for at least 8 months for males with female partners of reproductive potential |
Vismodegib | • Vismodegib monotherapy | • Arthralgia • Dermatologic toxicity • Muscle spasms • Increased creatine phosphokinase (CPK) • Premature epiphyseal fusion | • Ageusia • Alopecia • Anorexia • Constipation • Diarrhea • Dysgeusia • Fatigue • Nausea/vomiting • Weight loss | • Advise patients not to donate blood or blood products during treatment and for at least 24 months after the last dose • Advise males not to donate semen during and after therapy for 3 months after the last dose • Effective contraception required during and after therapy for 24 months for females of reproductive potential and for 3 months for males with female partners of reproductive potential |
Immune response modifier | ||||
Imiquimod | • Imiquimod monotherapy | • Skin weeping/erosion • Photosensitivity • Flu-like symptoms | • Edema • Erythema • Excoriation • Flaking/scaling/dryness • Induration • Pruritus • Scabbing/crusting • Skin burning • Ulceration | |
Programmed death receptor-1 (PD-1) blocking antibody | ||||
Cemiplimab | • Cemiplimab monotherapy | • Adrenal insufficiency • Colitis • Diabetic ketoacidosis • Exfoliative dermatitis • Hepatitis • Hyperthyroidism • Hypophysitis • Hypothyroidism • Infusion-related reactions • Myocarditis • Nephritis • Neurotoxicity • Pneumonitis • Thyroiditis | • Diarrhea • Fatigue • Musculoskeletal pain • Rash | • Effective contraception required during and after therapy for at least 4 months for females of reproductive potential |